Day One Biopharma R&D Head Samuel Blackman retiring; to advise

Day One Biopharmaceuticals, Inc.

Samuel Blackman, co-founder and Head of R&D, will retire effective end of 2024.
Blackman served as Head of R&D since May 2023; previously Chief Medical Officer since founding.
He will remain as a strategic advisor and consultant during search for successor.
Company has initiated search for new Head of Research & Development.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Samuel Blackman

Head of Research & Development

Day One Biopharmaceuticals, Inc.

Effective: 2024-12-31
Filed: November 20, 2024, 6:59 PM ET

On November 20, 2024, Samuel Blackman, M.D., Ph.D, notified Day One Biopharmaceuticals, Inc. (the “Company”) of his intention to retire from his position as Head of Research & Development of the Company effective at the end of 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Samuel Blackman departed as Head of Research & Development at Day One Biopharmaceuticals, Inc..

Action: retire
Role: Head of Research & Development

Exact text from the filing

On November 20, 2024, Samuel Blackman, M.D., Ph.D, notified Day One Biopharmaceuticals, Inc. (the “Company”) of his intention to retire from his position as Head of Research & Development of the Company effective at the end of 2024.

View on SEC.gov

Source: SEC EDGAR

accession 0001193125-24-262560

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.